BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 15508116)

  • 1. Stem cell clonality and genotoxicity in hematopoietic cells: gene activation side effects should be avoidable.
    von Kalle C; Fehse B; Layh-Schmitt G; Schmidt M; Kelly P; Baum C
    Semin Hematol; 2004 Oct; 41(4):303-18. PubMed ID: 15508116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1.
    Hacein-Bey-Abina S; Garrigue A; Wang GP; Soulier J; Lim A; Morillon E; Clappier E; Caccavelli L; Delabesse E; Beldjord K; Asnafi V; MacIntyre E; Dal Cortivo L; Radford I; Brousse N; Sigaux F; Moshous D; Hauer J; Borkhardt A; Belohradsky BH; Wintergerst U; Velez MC; Leiva L; Sorensen R; Wulffraat N; Blanche S; Bushman FD; Fischer A; Cavazzana-Calvo M
    J Clin Invest; 2008 Sep; 118(9):3132-42. PubMed ID: 18688285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Development and application of gene therapy technologies].
    Ozawa K
    Uirusu; 2004 Jun; 54(1):49-57. PubMed ID: 15449904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients.
    Howe SJ; Mansour MR; Schwarzwaelder K; Bartholomae C; Hubank M; Kempski H; Brugman MH; Pike-Overzet K; Chatters SJ; de Ridder D; Gilmour KC; Adams S; Thornhill SI; Parsley KL; Staal FJ; Gale RE; Linch DC; Bayford J; Brown L; Quaye M; Kinnon C; Ancliff P; Webb DK; Schmidt M; von Kalle C; Gaspar HB; Thrasher AJ
    J Clin Invest; 2008 Sep; 118(9):3143-50. PubMed ID: 18688286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Murine leukemias with retroviral insertions at Lmo2 are predictive of the leukemias induced in SCID-X1 patients following retroviral gene therapy.
    Davé UP; Akagi K; Tripathi R; Cleveland SM; Thompson MA; Yi M; Stephens R; Downing JR; Jenkins NA; Copeland NG
    PLoS Genet; 2009 May; 5(5):e1000491. PubMed ID: 19461887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. For gene therapy, now-quantified risks are deemed troubling.
    Twombly R
    J Natl Cancer Inst; 2003 Jul; 95(14):1032-3. PubMed ID: 12865444
    [No Abstract]   [Full Text] [Related]  

  • 7. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1.
    Hacein-Bey-Abina S; Von Kalle C; Schmidt M; McCormack MP; Wulffraat N; Leboulch P; Lim A; Osborne CS; Pawliuk R; Morillon E; Sorensen R; Forster A; Fraser P; Cohen JI; de Saint Basile G; Alexander I; Wintergerst U; Frebourg T; Aurias A; Stoppa-Lyonnet D; Romana S; Radford-Weiss I; Gross F; Valensi F; Delabesse E; Macintyre E; Sigaux F; Soulier J; Leiva LE; Wissler M; Prinz C; Rabbitts TH; Le Deist F; Fischer A; Cavazzana-Calvo M
    Science; 2003 Oct; 302(5644):415-9. PubMed ID: 14564000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A self-inactivating lentiviral vector for SCID-X1 gene therapy that does not activate LMO2 expression in human T cells.
    Zhou S; Mody D; DeRavin SS; Hauer J; Lu T; Ma Z; Hacein-Bey Abina S; Gray JT; Greene MR; Cavazzana-Calvo M; Malech HL; Sorrentino BP
    Blood; 2010 Aug; 116(6):900-8. PubMed ID: 20457870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapy.
    Aiuti A; Cassani B; Andolfi G; Mirolo M; Biasco L; Recchia A; Urbinati F; Valacca C; Scaramuzza S; Aker M; Slavin S; Cazzola M; Sartori D; Ambrosi A; Di Serio C; Roncarolo MG; Mavilio F; Bordignon C
    J Clin Invest; 2007 Aug; 117(8):2233-40. PubMed ID: 17671653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An experimental system for the evaluation of retroviral vector design to diminish the risk for proto-oncogene activation.
    Ryu BY; Evans-Galea MV; Gray JT; Bodine DM; Persons DA; Nienhuis AW
    Blood; 2008 Feb; 111(4):1866-75. PubMed ID: 17991809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Success for gene therapy: render unto Caesar that which is Caesar's.
    Qiao J; Diaz RM; Vile RG
    Genome Biol; 2004; 5(8):237. PubMed ID: 15287968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Foamy Virus Vector Carries a Strong Insulator in Its Long Terminal Repeat Which Reduces Its Genotoxic Potential.
    Goodman MA; Arumugam P; Pillis DM; Loberg A; Nasimuzzaman M; Lynn D; van der Loo JCM; Dexheimer PJ; Keddache M; Bauer TR; Hickstein DD; Russell DW; Malik P
    J Virol; 2018 Jan; 92(1):. PubMed ID: 29046446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stem cell gene therapy: the risks of insertional mutagenesis and approaches to minimize genotoxicity.
    Wu C; Dunbar CE
    Front Med; 2011 Dec; 5(4):356-71. PubMed ID: 22198747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ectopic retroviral expression of LMO2, but not IL2Rgamma, blocks human T-cell development from CD34+ cells: implications for leukemogenesis in gene therapy.
    Pike-Overzet K; de Ridder D; Weerkamp F; Baert MR; Verstegen MM; Brugman MH; Howe SJ; Reinders MJ; Thrasher AJ; Wagemaker G; van Dongen JJ; Staal FJ
    Leukemia; 2007 Apr; 21(4):754-63. PubMed ID: 17268520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene therapy resumes.
    Novak K
    Nat Rev Cancer; 2002 Nov; 2(11):813. PubMed ID: 12442759
    [No Abstract]   [Full Text] [Related]  

  • 16. Identification of a high incidence region for retroviral vector integration near exon 1 of the LMO2 locus.
    Yamada K; Tsukahara T; Yoshino K; Kojima K; Agawa H; Yamashita Y; Amano Y; Hatta M; Matsuzaki Y; Kurotori N; Wakui K; Fukushima Y; Osada R; Shiozawa T; Sakashita K; Koike K; Kumaki S; Tanaka N; Takeshita T
    Retrovirology; 2009 Sep; 6():79. PubMed ID: 19725963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene therapy for severe combined immunodeficiencies.
    Gaspar HB; Thrasher AJ
    Expert Opin Biol Ther; 2005 Sep; 5(9):1175-82. PubMed ID: 16120048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medicine. Gene therapy--new challenges ahead.
    Williams DA; Baum C
    Science; 2003 Oct; 302(5644):400-1. PubMed ID: 14563994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chance or necessity? Insertional mutagenesis in gene therapy and its consequences.
    Baum C; von Kalle C; Staal FJ; Li Z; Fehse B; Schmidt M; Weerkamp F; Karlsson S; Wagemaker G; Williams DA
    Mol Ther; 2004 Jan; 9(1):5-13. PubMed ID: 14741772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genotoxicity of retroviral integration in hematopoietic cells.
    Nienhuis AW; Dunbar CE; Sorrentino BP
    Mol Ther; 2006 Jun; 13(6):1031-49. PubMed ID: 16624621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.